Andrea F. Wainer - 14 Dec 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Signature
/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
14 Dec 2023
Net transactions value
-$954,000
Form type
4
Filing time
18 Dec 2023, 17:36:27 UTC
Previous filing
10 Aug 2023
Next filing
31 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $666,000 +15,000 +23% $44.40 80,027 14 Dec 2023 Direct
transaction ABT Common shares without par value Sale $1,620,000 -15,000 -19% $108.00 65,027 14 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -15,000 -28% $0.000000 38,271 14 Dec 2023 Common Shares 15,000 $44.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.